Leading Researcher of the Federal State Budgetary Institution of Science Murmansk Marine Biological Institute of the Russian Academy of Sciences (MMBI RAS), Candidate of Pharmaceutical Sciences. Head of the Research Group of Biochemistry of Hydrobionts (algae and invertebrates)
Ekaterina Obluchinskaya graduated from the Faculty of Industrial Technology of Drugs of the St. Petersburg State Chemical and Pharmaceutical University with a degree in Biotechnology (1997). In the same place she studied in postgraduate studies in the specialties 15.00.01 - drug technology and organization of pharmaceutical business, 03.00.07 - microbiology (1999-2003). Candidate of Pharmaceutical Sciences, specialty 15.00.01 - drug technology and organization of pharmaceutical business (2004). She defended her Ph.D. thesis on the topic: "Improvement of the complex technology of medicines from bladderwrack (Fucus vesiculosus L.)" (2004).
Direction of scientific research: development of scientific foundations for innovative technologies for processing bioresources of the Arctic; extraction and analysis of the properties of biologically active substances (BAS) of algae and invertebrates in accordance with the principles of "green chemistry"; the use of deep eutectic solvents for the extraction of biologically active substances; creation on their basis of preparations for biotechnology, medicine, food industry.
Author of the concept of rational use of algal resources. Scientific and practical achievements: Developed a patented technology for the complex processing of fucus algae with the production of highly purified and complex biologically active substances (RF Patent No. 2337571, 2008), as well as an original method for obtaining the active pharmaceutical substance fucoidan, which has an anticoagulant effect (RF Patent No. 2506089, 2014). Based on the active substance, she developed two dosage forms of a new anticoagulant drug - an ointment and tablets with fucoidan (RF Patent No. 2657615, 2018). The new substance fucoidan has passed a full cycle of preclinical studies with the financial support of the Federal Target Program "Development of the Pharmaceutical and Medical Industry of the Russian Federation for the period up to 2020 and beyond", based on it, drugs have been created for the treatment of thrombosis and thrombophlebitis of the veins of the lower extremities, which are recommended for clinical trials . In addition, he is the author of the original development of enzymatic hydrolysates from marine hydrobiont processing waste (RF Patent No. 2712747, 2020), introduced into existing production.
List of publications on еLIBRARY.RU
Phone number: (8152) 25-06-96
